Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04158336 · ClinicalTrials.gov registry record · Phase 1
A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors
A Phase 1 study, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 274
- Enrollment target
NCT04158336 is a Phase 1 study that has completed, run by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals. The registered enrollment target is 274 participants.
The verdict
NCT04158336, a Phase 1 study, has completed, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 274 participants
- Enrollment target
Study Summary
This is a Phase 1 open-label, multicenter study of ZN-c3 (also known as Azenosertib) monotherapy which consists of Dose Escalation, a Food Effect Cohort, and Dose Expansion.
Interventions
- DRUG Azenosertib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 274 participants |
| Start Date | 2019-11-01 |
| Est. Completion | 2025-05-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04158336
The ClinicalTrials.gov registry entry for NCT04158336 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 274 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Azenosertib is the first listed.
NCT04158336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04158336 about?
NCT04158336 is a clinical study titled "A Study of Azenosertib (ZN-c3) in Participants With Solid Tumors". This is a Phase 1 open-label, multicenter study of ZN-c3 (also known as Azenosertib) monotherapy which consists of Dose Escalation, a Food Effect Cohort, and Dose Expansion.
What is the current status of trial NCT04158336?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 274 participants. The study started on 2019-11-01. Estimated completion is 2025-05-06.
What interventions are being tested in trial NCT04158336?
The interventions under investigation include: Azenosertib (DRUG).
Who is sponsoring clinical trial NCT04158336?
This trial is sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.